RxDoctor Payments Data

Helena Fotiou, MD

Hospitalist · West Hollywood, CANPI 1700144946

Payments from drug & device makers

$1,231in general payments, 2019–2025

Across 11 payments — averaging $111.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$335
  • AbbVie$250
  • Boehringer Ingelheim$231
  • Otsuka America Pharmaceutical, Inc.$124
  • Lilly USA, LLC$119
  • Novartis$113
  • plus $59 from 1 others

What the payments were for

  • Food & beverage$1,231100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,231 in reported general payments places this provider in the 90th percentile of 2,469 hospitalist providers in California.

See all hospitalist providers in California

Medicare billing

Part B allowed, 2024
$351,841
Medicare patients
607
Services billed
2,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$41,657
FarxigaDapagliflozin Propanediol18$20,037
XareltoRivaroxaban60$17,067
JanuviaSitagliptin Phosphate24$12,325
LinzessLinaclotide18$10,385
Sevelamer Carbonate20$7,259
Janumet XrSitagliptin Phos/Metformin Hcl18$5,149
SantylCollagenase Clostridium Hist.12$3,850
Enoxaparin Sodium15$3,704
Daptomycin11$3,338
Gabapentin119$2,872
Tamsulosin Hcl105$2,654
Pantoprazole Sodium157$2,580
Atorvastatin Calcium132$2,376
Icosapent Ethyl22$2,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$335$17,06760 claims
AbbVieLinzess$250$10,38518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,469 hospitalist providers in California.

Other hospitalist in West Hollywood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →